Kinnate Biopharma Current Cash

Kinnate Biopharma (KNTE) currently reports a current cash of $57M as of December 2023. That compares with $29M in the prior-year period — up 94.8% year over year. Use the charts on this page to explore Kinnate Biopharma's current cash history and peer comparisons.

Kinnate Biopharma's current cash increased from $29M to $57M — a 94.8% year-over-year increase (period ending December 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Kinnate Biopharma reported $57M in current cash as of December 2023. That compares with $29M in the prior-year period — up 94.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current current cash of $57M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Kinnate Biopharma, and consider following KNTE for alerts when major investors trade the stock.

Kinnate Biopharma is classified in the Healthcare sector. On current cash, it currently shows $57M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing KNTE with unrelated industries.